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A lport Syndrome is a genetic disorder characterized by 
hematuria, which often leads to renal failure. It may also be 
accompanied by extra-renal alterations, such as: sensorineural 
hearing loss, and ocular abnormalities. Dominant forms 
related to the X chromosome and caused by mutations in the 
locus COL4A5 have been described, as well as an autossomic 
recessive form resulting from mutations in the locus COL4A3 
or COL4A4. An autossomic dominant type of AS has also 
been reported. The disease is caused by changes in the 
collagen type IV chains, where symptoms reflect the damage 
to the basal membrane of several organs. The α3.α4.α5(IV) 
networks are found in the kidneys, cochlea and eyes. The 
objective was to characterize AS in this group of patients. 
In the current literature review it was found that: 1. AS is 
characterized by hematuria that may develop into renal failure 
and can also be accompanied by extra-renal manifestations. 
Hearing loss is a frequent extra-renal finding and one of 
the first symptoms of AS, therefore representing a relevant 
factor in the prognosis of the renal disease; 2. It is a genetic 
disorder resulting from abnormalities in the chains of collagen 
type IV in the basal membranes; 3. The hearing loss in AS is 
typically sensorineural with variable intensities, progressive 
and symmetrical, affecting middle and high frequencies; 4. 
Otolaryngologists should include a urine test in the SNHL 
work-up. It is essential to have an otologist involved in the 
treatment of these patients.
Rev Bras Otorrinolaringol. 
V.71, n.6, 813-9, nov./dec. 2005
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INTRODUCTION
Hereditary nephritis associated with sensorineural 
hearing loss and ocular abnormalities is known as Alport’s 
Syndrome (AS)1.
Hurst, in 1923, described hereditary nephritis and 
Alport, in 19272, reviewing the same family, emphasized 
that hearing loss was an important characteristic in almost 
all members1-3. Sohar (1956) identified ocular defects 
present in patients with AS1.
AS is a hereditary syndrome characterized by he-
maturia, which frequently takes to renal failure4. It may 
be followed by extra-renal manifestations4. Many times, 
therefore, nephropathy is associated with hearing loss 
and ocular defects4. In Figure 1 we can see the complex 
structure of collagen type IV and in Figure 2 the cor-
responding three-dimensional model of chains α3.α4.α5 
(NC1 hexamere)5.
The purpose of the present study was to review 
clinical aspects of hearing loss in Alport’s Syndrome and 
to introduce the recent genetic and biomolecular advances 
in the area.
LITERATURE REVIEW
The estimated frequency of the gene responsible for 
AP is of 1 in 5,000, obtained in a broad study that observed 
300 cases in the population of 1.5 million inhabitants in 
Utah6. It is not associated with any race or geographical 
region6.
The prevalence of subjects with AS that needs di-
alyses/renal transplantation is of 3% in Europe and 2.2% 
in USA7.
Genetics
Two forms are recognized in the molecular genetic 
base of AS. The dominant X-linked form owing to muta-
tions of locus COL4A5 and the recessive autosomal form, 
resulting from mutations to loci COL4A3 or COL4A43. 
However, the genealogical analysis suggests a dominant 
autosomal type. In approximately 85% of the cases of AS 
there is the X-linked dominant form and in 15% there is 
a recessive autosomal form8.
The six genes of collagen type IV are arranged 
in pairs in three different chromosomes. Human chains 
α1 and α2 are codified by genes COL4A1 and COL4A2, 
in head-to-hear pairing, respectively of chromosome 13. 
Genes COL4A3 and COL4A4 codify chains α3 and α4 of 
collagen type IV, respectively, and they are head-to-head 
paired in chromosome 2. Chains α5 and α6 (IV) are codi-
fied, respectively, by genes COL4A5 and COL4A6, in the 
long arm of chromosome X3.
Mutations of gene COL4A5 can possibly explain all 
cases of AS X-linked9.
Alpha chains can be divided into 3 domains: domain 
Figure 1. Set-up and organization of collagen type IV network (Hudson 
et al., 2003).
Figure 2. Three-dimension model of hexamere NC1 α3.α4.α5(IV). 
In red α3, in blue α4 and in green α5. Locations EA (yellow) and EB 
(golden) represent the domains for autoantibodies of Goodpasture’s 
syndrome (Hudson et al., 2003).
Figure 3. Genomic organization of six collagen genes type IV that are 
distributed in chromosomes 13, 2 and X. The 5 exons in portion 3’ 
terminal of COL4A5, codify the domain NC1 of α5(IV) and are shown 
in red (Kashtan & Michael, 1996).
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7S, amino-terminal (NH2, with approximately 15 amino ac-
ids); central triple-spiral domain (with approximately 1,400 
amino acids) and the non-collagenous carboxyl-terminal 
globular portion (NC1; COOH with close to 230 amino 
acids)3. The main sequence is comprised by glycine (Gly), 
hydroxylysine (X) and hydroxyproline (Y)10 (Figure 3).
To understand AP it is necessary to get to know 
collagen IV type structure. There are six alpha chains. 
Chains α1 and α2 are named classical chains and chains 
α3, α4, α5 and α6 are named new chains. The six alpha 
chains, genetically distinct, are arranged in three pro-col-
lagen triple-spiral structures that differ in the composition 
of the chains (Figure 4)5.
The formation of collagen IV precursor molecule 
starts its interaction of domain NC1. The combination of 
a specific trimer starts when the 3 domains NC1 start a 
still unknown molecular interaction with the three alpha 
chains. The next step is the formation of collagen IV dimer. 
Four precursor molecules interact in the glycosylated 7S 
amino-terminal region (NH2) to form tetramers. These 
interactions form the nucleus of the collagen type IV struc-
ture that progresses to a supra-structure, with the support 
of terminal-terminal and also lateral associations10.
Chains α1 and α2 (IV) are present in all basal mem-
branes. Chains α3, α4 and α5(IV) are selectively expressed 
in basal membranes of some tissues, including the poten-
tially affected in AS, which are: the kidney (glomerular 
basal membrane / MBG and tubular basal membrane), the 
cochlea and the eye. Chains α5 and α6 (IV) are character-
istics of the skin, smooth muscle, esophagus and kidney 
(Bowman capsule)3.
Figure 5. Formation of type IV collagen network (Kalluri, 2003).
Figure 4. Triple-spiral organization of the family of collagen type IV. 
The selection of chains for the association in one precursor molecule 
is governed by the recognition of the domains NC1 (Hudson et al., 
2003).
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A mutation in one of the chains prevents incorpora-
tion of the other two stable triple helices11.
Type IV collagen is the main component of basal 
membranes. The mutation presented in AS produces 
defects in chains α3, α4 and α5 (IV). Type IV collagen 
damage, owing to mutation, breaks with the epithelial 
bonds and leads to organ defect. These defects in chains 
result in entanglement and incorrect set-up of monomers, 
which are quickly degraded. These mutations interrupt the 
normal replacement of the embryonic development and 
cause persistence of chains α1.α1.α2(IV) in renal basal 
membranes, cochlea and capsule of lenses. The embryonic 
network α1.α1.α2 (IV) is more susceptible to proteolysis 
than α3.α4.α5(IV), because the latter has strong bonds5.
Clinical Presentation and Diagnostic Criteria
These signs are observed in the clinical presenta-
tion of AS:
• Hematuria: the microscopic form is the most 
common one and the macroscopic form is second. Men 
present persistent microscopic hematuria, with episodes 
of coarse hematuria triggered by upper airway infections 
12. Proteinuria is less than 1 to 2g of excreted proteins 
per day 4,5.
• Progressive renal failure4
• Sensorineural hearing loss (SNHL) 4: variable 
intensity, bilateral, symmetrical and progressive. Present 
in approximately 55% of men and 45% of women7.
• Ocular affections4: anterior lenticonus (conical or 
spherical protrusion of the anterior surface of lenses to the 
anterior chamber; known as oil drop signal; occurs in 10 
to 30% of the cases; it is pathognomonic of AS)3,11, ocular 
stains and cataracts.
• Others4: macro-thrombocytopenia and leiomyo-
matosis.
The diagnostic criteria that should be employed are: 
family history of hematuria, with or without chronic renal 
failure; electron microscopic evidence of AS, in the sample 
of renal biopsy (variable thickness of MBG, with lamel-
lar dense lamina, circumscribing clear areas that contain 
electro-dense granules, present in 60 to 90% of the cases); 
characteristic ophthalmic signals previously described and 
sensorineural loss in high frequencies12.
Three or more criteria should be met12. As to clinical 
course of AS, progression is quicker and more predictable 
in men than in women. In women, the clinical course is 
more variable, and it is possible to have a normal and 
long-lasting life. In men, hematuria lasts the whole life12.
Boys develop12:
• Hematuria in childhood
• Progressive SNHL during school years
• Chronic renal failure
• Onset of ocular signs: 20 years
The diagnosis of AS is based on family history and 
clinical investigation of all family members, in addition to 
case index (family member that is affected and through 
whom the whole family is tested)11. Such information is 
the golden standard for diagnosis of AS. Hematuria is the 
most frequent affection8. SNHL in high frequencies is one 
of the most useful signs in a patient with hematuria and 
suggests the diagnosis in the absence of renal biopsy or 
family history of renal disease12.
Hearing loss is one of the first signs of AS1,7,12. It 
becomes evident at the end of childhood or beginning of 
adolescence in boys with X-linked disease and the progres-
sion suggests poor prognosis of renal disease13.
Upon analyzing 51 patients with AS that showed 
hearing loss, three audiometric configurations were 
identified: the ascending curve in 47.1% of the cases; the 
descending curve in 41.2% and the flat curve in 11.7% of 
the cases. The mean of thresholds in 500, 1000 and 2000 
Figure 6. Classification of 51 audiometries by type of configuration: (A) ascending, (B) descending and (C) flat (Rintelmann, 1976).
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Hz was 33dB HL in flat curve; 42 dB HL in ascending 
curve and 50 dB HL in descending curve. Flat curve was 
seen at the age of 8.5 years; ascending at 13.7 years and 
descending at 17.8 years, which could suggest a progres-
sion of the curve (Figure. 6)14.
The assessment of 11 patients with AS, confirmed 
histologically, has demonstrated speech reception thresh-
olds compatible with the means of pure tone and speech 
recognition index in compliance with audiometric con-
figuration. We observed more significant recruitment in 
middle frequencies. Latencies of waves I, III and V and 
intervals I-V and III-V were normal in this description of 
the auditory brainstem responses (ABR), confirming the 
integrity of retrocochlear pathways and indicating that the 
defect was located in the cochlea1.
Other hereditary nephritis with hearing loss should 
be excluded, such as: hyper-prolinemia, Charcot-Marie-
Tooth disease and hereditary interstitial nephritis6.
Animal Studies
The following observations were made in animal 
models: basal membranes are the main constituents of 
membranous labyrinth and the most common component 
of basal membrane is type IV collagen15,16.
Chains a3(IV), a4(IV), a5(IV) and a6(IV) are ex-
clusively located in tectorial and basilar membranes 
of the cochlea of normal guinea pigs by indirect 
immunofluorescence17. These results suggest that a pos-
sible function of the chains of type IV collagen is the active 
adjustment of basilar and tectorial membranes, a essential 
stage in the discrimination of frequencies and amplification 
of auditory signs17.
Electron microscopic examination in mutant rats 
(Knockout rats in which one specific gene was marked, 
and the model is used for recessive autosomal AS) re-
vealed: thinning of cochlear basal membrane and affection 
of stria vascularis, with edema in endothelial cells and 
reduction of the internal diameter of capillaries18. Thinning 
of basal membrane along the basilar membrane may have 
some effect on the rigidity of the membrane and affections 
to stria vascularis may restrict the blood flow through the 
metabolically hyperactive tissue18.
Studies in dogs Samoyed (X-linked animal model 
of AS) demonstrated absence of chains a3, a4 and a5 in 
spiral ligament19. The absence of these chains in the region 
could result in reduced capacity of myofibroblasts to main-
tain enough tension in the basilar membrane, with loss of 
perception for high sounds. The supposed site for hearing 
affection in human AS is the spiral ligament19.
DISCUSSION
Hearing loss is one of the first and most useful 
signs in patients with hematuria. SNHL in high frequen-
cies suggests the diagnosis of AS even in the absence of 
renal biopsy or family history of renal failure. Biopsy may 
be risky in cases of renal failure3,11 and family history is 
negative in isolated cases of de novo mutation8.
Otorhinolaryngologists should suspect of the affec-
tion and include the urine exam in investigation of hearing 
losses1. Children with unexplained hematuria,. adolescents 
and middle-age men in end-stage renal failure and patients 
with family history of renal disease in siblings or maternal 
relatives should perform the microscopic exam of urinary 
sediment6. It is important to count on the contribution of 
the geneticist for the investigation about type of heredity, 
to guide about the available exams for genetic investiga-
tion and to counsel the patient and family. The contribu-
tion of ophthalmologist in patients with suspicion of AS is 
important because anterior lenticonus is pathognomonic 
and it is consistently associated with quick progression to 
renal failure and hearing loss11.
The methods for auditory assessment (audiometry, 
ABR and otoacoustic emissions) should be employed in 
the investigation of the index case and the other family 
cases (affected and asymptomatic) to investigate all disease 
holders. The diagnosis of people with genetic diseases 
is extremely valuable in counseling patients and family 
members20.
Careful follow-up of the hearing loss is a relevant 
factor of the prognosis of the renal disease progression. 
Men with hearing loss in the first two decades of life had 
more severe renal disease13.
The accumulation of metabolites could have an 
ototoxic effect21. However, there are many reports of SNHL 
that precedes or occurs in the absence of renal affections7. 
The similarities between the kidney and the cochlea, con-
cerning regulation of post-natal development of type IV 
collagen chains suggest that otological affection in AS is 
resultant from a defect in cochlear basal membranes and 
not because of renal impairment5,16.
As to auditory investigation, many recent advances 
occurred by the use of guinea pigs and animal models for 
hearing loss in human AS. They allowed the understanding 
of normal hearing at molecular level and the mechanisms 
that are affected when there is one specific mutation22. 
Investigations in Knockout COL4A3 rats suggested affec-
tions to stria vascularis as the cause of hearing loss in AS 
18 and in Samoyed dog, inner ear spiral ligament may be 
responsible for SNHL in low sounds19. Studies in human 
ears in patients with AS are restricted because of difficulties 
to reach the temporal bones, the limited number of studied 
pieces, difficulties to fix and the process of autolysis after 
death, contributing to the differences observed in the de-
scriptions of these temporal bones in the literature16.
Treatment and Perspectives
The regular assessment of hearing in patients with 
AS is very important. Ocular abnormalities in these patients 
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hinder visual clues, which are essential for the communica-
tion with patients who have severe hearing loss. Careful 
rehabilitation of hearing loss is essential1.
As to treatment of AS, dialysis and renal trans-
plantation are indicated in this group of patients with AS 
and end-stage renal failure. During hemodialysis, there 
are osmotic affections and electrolytic affections in en-
dolymph. Patients submitted to renal transplantation use 
immunosuppressant drugs (cyclosporine A and corticoids) 
that cause affection to viscosity of plasma and circulation 
of inner ear. Therefore, these patients require otological 
follow-up1,3,6,11,23.
Prognosis improves with renal transplantation, 
increasing longevity of patients with AS and renal failure. 
Therefore, the follow up, rehabilitation and investigation 
of the progression of hearing loss become important in 
the quality of life of these patients1.
Some authors reported improvement or stabiliza-
tion of hearing loss in post-transplantation patients1,21, but 
others reported worsening of hearing23. With improvement 
after transplantation it is easier to understand that there is 
stabilization or even slower progression of hearing loss, 
given that the basal membrane affection, resulting from 
collagen IV, is gone. Additional studies are required to 
understand the progression of auditory affection in this 
group of post-renal transplantation patients.
It is possible to build a profile of these patients that 
can develop anti-MBG nephritis after renal transplantation: 
normally they are men, always with hearing loss and they 
have end-stage renal failure before the age of 30 years3.
Anti-MBG nephritis, after renal transplantation, is 
rare but severe, and it is important to predict its occur-
rence; hearing assessment may contribute to create this 
risk profile.
Genetic therapy has been investigated in Samoyed 
dogs (X-linked animal model of AS). The use of an ad-
enoviral vector, codifying the chain a5(IV) of collagen in 
cells of smooth muscle of bladder of these animals corrects 
the defect and restores the expression of chains a5 and 
a624. It is wondered which phase of the renal disease is 
appropriate to this modality of treatment3. To maintain the 
expression of these chains, which used to be unknown to 
the host, it requires immunosuppression and it is discussed 
what would be the best vector3. Studies related to cochlear 
genetic therapy contribute to the molecular genetic analysis 
of hearing; experimentally, the skill to introduce genes 
in the inner ear may lead to elucidation of the function 
of cochlear proteins and the control of specific inner ear 
genes25. The methods of vector introduction include infu-
sion by mini-probing or microinjection in the tympanic 
scala, through the round window25.
It is necessary to make some comments about 
the disorder. The nail-patella syndrome results from 
dominant autosomal mutation in the transcription factor 
LMX1B, which regulates genes COL4A3 and COL4A4 and 
the children have nephrotic syndrome and skeletal and 
nail dysplasia5. Goodpasture’s syndrome is an immune 
disorder with serum antibodies directed against specific 
regions of chain α3 (IV) of type IV collagen and patients 
present pulmonary hemorrhage with nephritis; it is fatal if 
not treated. Therefore, the pathogenesis of AS and Good-
pasture’s syndrome is linked to the same pro-collagen 
α3.α4. α5(IV)5. Patients with uncontrolled diabetes mellitus 
develop progressive glomerulonephritis associated with 
SNHL and degenerative retina disease; it has already been 
confirmed by immunofluorescence that in the kidney and 
in the retina of these patients RNAm COL4A1 and RNAm 
COL4A2 are elevated by the activation of a secondary 
route of glycosylated metabolites15. Studies in this area 
can provide further knowledge about the diseases related 
with collagen.
CONCLUSION
After the critical analysis of the literature, we drew 
the following conclusions:
1. AS is characterized by hematuria that progresses 
to renal failure and may be followed by extra-renal mani-
festations. Hearing loss is a frequent extra-renal finding 
and one of the first symptoms of AS, which is a relevant 
factor of the prognosis of renal disease progression.
2. AS is a genetic disease and results from affections 
to collagen IV chains in basal membranes.
3. There is sensorineural hearing loss, of variable 
intensity, progressive and symmetrical. It affects medium 
and high frequencies.
4. For the investigation of SNHL in children with 
hematuria, in male adolescents and adults with end-stage 
renal failure, in patients with family history of renal disease 
in siblings or maternal relatives, we should also include 
urine exam.
5. The otologist should follow up these patients. 
Ophthalmologic and genetic examinations should be 
ordered to provide counseling to the patients and the 
family members.
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